Effect of Armodafinil on Simulated Driving

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 21, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

armodafinil

Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test

DRUG

Placebo (for armodafinil)

Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test

Trial Locations (1)

32610

University of Florida, Clinical and Translational Science Institute, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT02468856 - Effect of Armodafinil on Simulated Driving | Biotech Hunter | Biotech Hunter